Loading...
  • broadly reactive
  • Although the Thai RV144 vaccine trial has demonstrated an efficacy of 31.2%, an effective vaccine will likely rely on a breakthrough discovery of immunogens to elicit broadly reactive neutralizing antibodies, which may take years to achieve. (springer.com)
  • LYMPHOMA
  • Although 1F5 could activate human T cells when combined with T-cell receptor stimulation, 1F5 did not promote the survival or proliferation of freshly isolated lymphoma cells from patients. (aacrjournals.org)
  • The purpose of this study is to determine the long-term safety of a fixed-dose, daily regimen of PCI-32765 PO in subjects with B cell lymphoma or chronic lymphocytic leukemia/small lymphoc. (bioportfolio.com)
  • A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia. (bioportfolio.com)
  • Histiocytic Sarcoma: Review, Discussion of Transformation From B-Cell Lymphoma, and Differential Diagnosis. (bioportfolio.com)
  • Histiocytic sarcoma is a rare neoplasm of mature histiocytes with an aggressive clinical course that can arise de novo or from a low-grade B-cell lymphoma. (bioportfolio.com)
  • Non-Hodgkin lymphoma (NHL) is a heterogeneous group of B-cell malignancies with a considerable amount of genetic diversity, reflecting the differentiation status at the time of lymphocyte transformation ( 1 ). (aacrjournals.org)
  • gp41
  • The levels of antibody against the gp120 CD4 binding site, gp41, as well as Env epitopes near to the sites bound by broadly nAbs 2F5 and 1b12 were not different between HICs and viremic individuals. (ovid.com)
  • vaccine
  • A clinical Phase I study in patients with recurrent ovarian carcinoma showed that 67% of the patients developed specific anti-anti-Id antibody (Ab3) directed against the vaccine. (aacrjournals.org)
  • therapy
  • αβ T-cell receptor bias in disease and therapy (Review). (semanticscholar.org)
  • Targeting of the human epithelial receptor type 2 (HER2)-neu receptor by specific antibodies is a recent well-established therapy for breast tumours. (nih.gov)
  • rituximab
  • Western blotting and flow cytometry were used to contrast the signaling pathways activated by dacetuzumab and rituximab in NHL cells. (aacrjournals.org)
  • Rituximab signaling downregulated BCL-6 oncoprotein in a cell line-specific manner, whereas dacetuzumab strongly downregulated BCL-6 in each cell line. (aacrjournals.org)
  • In addition to effector function activity, rituximab is a signaling antibody capable of suppressing antiapopototic pathways and chemosensitizing drug-resistant NHL cells ( 5-7 ). (aacrjournals.org)
  • marker
  • The NKp46 cell surface marker constitutes, at the moment, another NK cell marker of preference being expressed in both humans, several strains of mice (including BALB/c mice ) and in three common monkey species. (wikipedia.org)
  • conformational
  • Significantly, Env conformational changes induced by cell surface CD4 are conserved among Env from HIV-1 and HIV-2/SIVmac lineages. (duke.edu)
  • hematopoietic
  • As previously described,23 CD1d was expressed on hematopoietic cells, such as Jurkat and THP‐1 cells (Fig. 1b), but it was not expressed on the surface of NB cell lines (Fig. 1a). (nih.gov)